Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
25 07 2023
25 07 2023
Historique:
received:
07
11
2022
accepted:
03
04
2023
medline:
26
7
2023
pubmed:
1
6
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
Sleep disordered breathing (SDB) has been related to amyloid deposition and an increased dementia risk. However, how SDB relates to medial temporal lobe neurodegeneration and subsequent episodic memory impairment is unclear. Our objective was to investigate the impact of amyloid positivity on the associations between SDB severity, medial temporal lobe subregions, and episodic memory performance in cognitively unimpaired older adults. Data were acquired between 2016 and 2020 in the context of the Age-Well randomized controlled trial of the Medit-Aging European project. Participants older than 65 years who were free of neurologic, psychiatric, or chronic medical diseases were recruited from the community. They completed a neuropsychological evaluation, in-home polysomnography, a Florbetapir PET, and an MRI, including a specific high-resolution assessment of the medial temporal lobe and hippocampal subfields. Multiple linear regressions were conducted to test interactions between amyloid status and SDB severity on the volume of MTL subregions, controlling for age, sex, education, and the ApoE4 status. Secondary analyses aimed at investigating the links between SDB, MTL subregional atrophy, and episodic memory performance at baseline and at a mean follow-up of 20.66 months in the whole cohort and in subgroups stratified according to amyloid status. We included 122 cognitively intact community-dwelling older adults (mean age ± SD: 69.40 ± 3.85 years, 77 women, 26 Aβ+ individuals) in baseline analyses and 111 at follow-up. The apnea-hypopnea index interacted with entorhinal (β = -0.81, Overall, we showed that SDB was associated with MTL atrophy in cognitively asymptomatic older adults engaged in the Alzheimer continuum, which may increase the risk of developing memory impairment over time. ClinicalTrials.gov Identifier: NCT02977819.
Sections du résumé
BACKGROUND AND OBJECTIVES
Sleep disordered breathing (SDB) has been related to amyloid deposition and an increased dementia risk. However, how SDB relates to medial temporal lobe neurodegeneration and subsequent episodic memory impairment is unclear. Our objective was to investigate the impact of amyloid positivity on the associations between SDB severity, medial temporal lobe subregions, and episodic memory performance in cognitively unimpaired older adults.
METHODS
Data were acquired between 2016 and 2020 in the context of the Age-Well randomized controlled trial of the Medit-Aging European project. Participants older than 65 years who were free of neurologic, psychiatric, or chronic medical diseases were recruited from the community. They completed a neuropsychological evaluation, in-home polysomnography, a Florbetapir PET, and an MRI, including a specific high-resolution assessment of the medial temporal lobe and hippocampal subfields. Multiple linear regressions were conducted to test interactions between amyloid status and SDB severity on the volume of MTL subregions, controlling for age, sex, education, and the ApoE4 status. Secondary analyses aimed at investigating the links between SDB, MTL subregional atrophy, and episodic memory performance at baseline and at a mean follow-up of 20.66 months in the whole cohort and in subgroups stratified according to amyloid status.
RESULTS
We included 122 cognitively intact community-dwelling older adults (mean age ± SD: 69.40 ± 3.85 years, 77 women, 26 Aβ+ individuals) in baseline analyses and 111 at follow-up. The apnea-hypopnea index interacted with entorhinal (β = -0.81,
DISCUSSION
Overall, we showed that SDB was associated with MTL atrophy in cognitively asymptomatic older adults engaged in the Alzheimer continuum, which may increase the risk of developing memory impairment over time.
TRIAL REGISTRATION INFORMATION
ClinicalTrials.gov Identifier: NCT02977819.
Identifiants
pubmed: 37258299
pii: WNL.0000000000207421
doi: 10.1212/WNL.0000000000207421
pmc: PMC10435067
doi:
Substances chimiques
pentaerythrityl triacrylate
PJJ1161ULF
Acrylates
0
Amyloid
0
Amyloidogenic Proteins
0
Amyloid beta-Peptides
0
Banques de données
ClinicalTrials.gov
['NCT02977819']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e370-e385Subventions
Organisme : NIA NIH HHS
ID : R01 AG056014
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG069474
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
J Alzheimers Dis. 2017;59(1):21-29
pubmed: 28550245
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Neurobiol Aging. 2018 Jun;66:49-58
pubmed: 29518752
Eur Respir J. 2012 Aug;40(2):386-93
pubmed: 22241742
Neurology. 2002 Mar 12;58(5):750-7
pubmed: 11889239
Neuroscience. 2015 Nov 19;309:259-79
pubmed: 26383255
Nat Med. 2019 Apr;25(4):554-560
pubmed: 30911133
Hippocampus. 2020 Jun;30(6):545-564
pubmed: 31675165
Am J Respir Crit Care Med. 2017 Jun 1;195(11):1509-1518
pubmed: 28060546
J Clin Sleep Med. 2017 May 15;13(5):665-666
pubmed: 28416048
Neuroimage Clin. 2018 Jul 27;20:305-317
pubmed: 30101062
JAMA Neurol. 2020 Jun 1;77(6):716-724
pubmed: 32202593
Nat Rev Neurosci. 2011 Sep 07;12(10):585-601
pubmed: 21897434
Hum Brain Mapp. 2015 Jan;36(1):258-87
pubmed: 25181316
Neurobiol Aging. 2012 Jul;33(7):1253-7
pubmed: 21489655
Neurosci Biobehav Rev. 2016 Jun;65:142-56
pubmed: 27039344
Eur Respir J. 2018 Jul 4;52(1):
pubmed: 29973356
Am J Respir Crit Care Med. 2018 Apr 1;197(7):933-943
pubmed: 29125327
J Neurochem. 1997 Aug;69(2):883-6
pubmed: 9231752
Lancet Neurol. 2013 Apr;12(4):357-67
pubmed: 23477989
Front Aging Neurosci. 2010 Mar 30;2:12
pubmed: 20552050
J Neurosci. 2019 Feb 13;39(7):1320-1331
pubmed: 30587544
Sleep Med. 2022 Mar;91:21-30
pubmed: 35245788
Neuroscience. 2015 Nov 19;309:29-50
pubmed: 26306871
Neuroscience. 1991;40(3):599-636
pubmed: 1676492
Am J Respir Crit Care Med. 2011 May 15;183(10):1419-26
pubmed: 21037021
Alzheimers Dement (N Y). 2018 Dec 14;4:714-723
pubmed: 30581977
Neuroimage Clin. 2022;36:103235
pubmed: 36272339
J Cereb Blood Flow Metab. 2015 Nov;35(11):1836-45
pubmed: 26082014
Ageing Res Rev. 2016 Sep;30:25-48
pubmed: 26827786
Curr Neurol Neurosci Rep. 2021 Feb 14;21(3):11
pubmed: 33586028
Ann Neurol. 2020 Jun;87(6):921-930
pubmed: 32220084
Neuroimage. 2010 May 15;51(1):488-99
pubmed: 20083211
Brain Sci. 2021 May 27;11(6):
pubmed: 34071739
Sleep Med. 2019 Feb;54:195-204
pubmed: 30580194
Ann Neurol. 2011 Jan;69(1):181-92
pubmed: 21280088
Sleep. 2019 Jan 1;42(1):
pubmed: 30346595
Alzheimers Dement. 2020 Oct 8;:
pubmed: 33090679
Hum Brain Mapp. 2019 Aug 15;40(12):3431-3451
pubmed: 31034738
Neuroimage. 2012 Feb 15;59(4):3309-15
pubmed: 22119654
J Neurosci Res. 2015 Dec;93(12):1778-94
pubmed: 26301370
Sleep Med Rev. 2017 Aug;34:70-81
pubmed: 27568340
PLoS One. 2013 Dec 13;8(12):e83173
pubmed: 24349453
Neuropsychologia. 2009 Jul;47(8-9):1765-79
pubmed: 19428409
J Neurosci. 2017 Apr 19;37(16):4280-4288
pubmed: 28320844
Neurobiol Dis. 2020 Nov;145:105054
pubmed: 32860945
JAMA Neurol. 2017 Oct 1;74(10):1237-1245
pubmed: 28846764
Sleep. 2014 Jan 01;37(1):167-75
pubmed: 24470705
Neurosci Lett. 2018 Aug 24;682:118-123
pubmed: 29883682